Back
  1. Home
  2. Profile of Aline Genbauffe (UMONS)
Profil

Genbauffe Aline

Université de Mons - UMONS > Faculté de Médecine et de Pharmacie > Service de Biologie humaine et Toxicologie

Université de Mons - UMONS > Recherche > Service de l'Institut des Sciences et Technologies de la santé

Main Referenced Co-authors
JOURNE, Fabrice  (2)
Soumoy, Laura  (2)
BLANKERT, Bertrand  (1)
Ghanem, Ghanem (1)
Lefranc, Florence (1)
Main Referenced Keywords
Bufalin (2); ATP1A1 (1); Cancer Research (1); Cardiotonic steroid (1); Clinical Trial (1);
Main Referenced Disciplines
Oncology (2)
Chemistry (1)
Physical, chemical, mathematical & earth Sciences: Multidisciplinary, general & others (1)

Publications (total 2)

The most downloaded
42 downloads
Soumoy, L., Genbauffe, A., Mouchart, L., Sperone, A., Trelcat, A., Mukeba-Harchies, L., Wells, M., Blankert, B., Najem, A., Ghanem, G., Saussez, S., & Journe, F. (04 January 2024). ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. Cancer Cell International, 24 (1), 8. doi:10.1186/s12935-023-03196-y https://hdl.handle.net/20.500.12907/48079

The most cited

4 citations (Scopus®)

Soumoy, L., Genbauffe, A., Mouchart, L., Sperone, A., Trelcat, A., Mukeba-Harchies, L., Wells, M., Blankert, B., Najem, A., Ghanem, G., Saussez, S., & Journe, F. (04 January 2024). ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. Cancer Cell International, 24 (1), 8. doi:10.1186/s12935-023-03196-y https://hdl.handle.net/20.500.12907/48079

Genbauffe, A., Soumoy, L., Lefranc, F., & Journe, F. (September 2024). Reviewing Clinical Trials and Meta-Analyses to Assess the Efficacy and Safety of Huachansu in Cancer Treatment. Journal of Biomedical Research & Environmental Sciences, 5 (9), 1132-1139. doi:10.37871/jbres2001
Peer reviewed

Soumoy, L., Genbauffe, A., Mouchart, L., Sperone, A., Trelcat, A., Mukeba-Harchies, L., Wells, M., Blankert, B., Najem, A., Ghanem, G., Saussez, S., & Journe, F. (04 January 2024). ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. Cancer Cell International, 24 (1), 8. doi:10.1186/s12935-023-03196-y
Peer Reviewed verified by ORBi

Contact ORBi UMONS